Detailed Narrative
Q1 FY26 Performance Overview Amidst Volatility
Clean Science reported a challenging Q1 FY26 marked by heightened global volatility🌐 and extended client decision cycles. Standalone revenue decreased by 9% sequentially to INR217 crores, with consolidated sales also down 6% sequentially to INR240 crores. Despite this, the company achieved a record high standalone EBITDA margin of over 46% and a consolidated EBITDA of INR100 crores, implying a 42% margin. The Pharma segment experienced a 29% sequential decline, while non-established products faced softer demand.
Product Mix and Margin Expansion
A favorable product mix was a key driver for margin expansion in Q1 FY26. Established products contributed 83% to standalone sales, up from 75% in Q4 FY25 and 80% in Q1 FY25. This shift led to a significant 13% sequential and 4% annual improvement in Raw Material Cost (RMC). The highest ever standalone EBITDA margin of over 46% was attributed to this product mix, where established products generally have better margins than non-established ones.
New Product Commercialization and Capex Update
Clean Science invested INR80 crores in its subsidiary, Clean Fino-Chem Limited, during Q1. The construction of Performance Chemical 1 is on track for commercialization in September 2025, with water trials expected in the next four weeks. Capex for Performance Chemical 2 is also underway, targeting commercialization by Q4 FY26. The Pharma Intermediate DHDT has been commercialized, and samples are being sent for validation. Additionally, the company is repurposing its PBQ facility to produce Barbituric acid, with commercialization estimated by August end.
HALS Business Performance and Strategy
The HALS business saw an 8% sequential increase in sales, reaching INR24 crores with a volume of 580 tons in Q1. Domestic sales accounted for 73% of HALS revenue. Management reiterated its FY26 target of INR210 crores for HALS, banking on the introduction of newer, more expensive grades (priced $11-$35 per kg) in the next two quarters to boost margins. The company also clarified that its HALS subsidiary is nearing EBITDA breakeven at a monthly run rate of INR10 crores in sales.
Market Conditions and Outlook
The company noted a challenging global market with heightened volatility, trade uncertainties, and geopolitical tensions, leading to extended client decision cycles. China and Europe were particularly slow. While established products maintained momentum, non-established products experienced softer demand. The EBITDA growth guidance for FY26 was moderated from 18-20% to 15-18%, reflecting these conditions, though management expects contributions from new launches to support growth.
Promoter Shareholding Update
A significant update regarding promoter shareholding was provided: a faction of the Boob family intends to reduce their stake. The total promoter stake, currently at 75%, will decrease to 51%, with the 24% difference being sold by this family faction. Management clarified that this is for estate planning purposes and will not affect the company's business operations or the involvement of the current management.